|
DE102011006425A1
|
|
Pharmaceutical composition, useful for treating and/or preventing e.g. Parkinson's disease, dementia, neuropathic pain, retinitis pigmentosa, multiple sclerosis and amyotrophic lateral sclerosis, comprises flupirtine and N-acetylcysteine
|
|
DE102010063609A1
|
|
New multicomponent crystals of ([2-amino-6- (4-fluoro-benzylamino) -pyridin-3yl) -carbamic acid ethyl ester and an arylpropionic acid
|
|
DE102010063612A1
|
|
New multicomponent crystals of [2- [2-amino-6- (4-fluoro-benzylamino) -pyridin-3-yl] -carbamic acid ethyl ester and 2- [2 - [(2,6-dichlorophenyl) -amino] -phenyl] -acetic acid
|
|
DE102010030053A1
|
|
Injectable dosage form of flupirtine
|
|
EP2346826A2
|
|
Carboxylic acid salts of 2-amino-3-carbethoxyamino-6-(4-fluoro-benzylamino)-pyridine
|
|
WO2009152142A1
|
|
Sulfonate salts of flupirtine
|
|
EP2206699A1
|
|
Crystalline form of flupirtine ((2-amino-6-(4-fluoro-benzylamino)-pyridin-3-yl)-carbamic acid ethyl ester)
|
|
EP2206700A1
|
|
Crystalline form of flupirtine ((2-amino-6-(4-fluoro-benzylamino)-pyridin-3-yl)-carbamic acid ethyl ester)
|
|
EP2206701A1
|
|
Crystalline form of flupirtine ((2-amino-6-(4-fluoro-benzylamino)-pyridin-3-yl)-carbamic acid ethyl ester)
|
|
DE102005054610A1
|
|
Controlled-release drug preparation containing flupirtine
|
|
US2006029670A1
|
|
Pharmaceutical Formulations and Method for Making
|
|
DE10327674A1
|
|
Injectable dosage form of flupirtine
|
|
YU66902A
|
|
Pharmaceutical preparations containing saccharose fatty acid esters for controlling the release of active ingredients
|
|
PL362547A1
|
|
Pharmaceutical preparations containing saccharose fatty acid esters for controlling the release of active ingredients
|
|
IL147667D0
|
|
Use of flupiritine for alleviating pain caused by degenerative joint diseases in dogs and cats
|
|
DE4423078A1
|
|
A process for the preparation of a sustained-release carbamazepine dosage form
|
